What Is Retatrutide? A Quick Research Overview

By NorthPeptide Research Team · April 5, 2026

A New Class of Metabolic Peptide

Retatrutide — also designated LY3437943 — is a synthetic peptide developed by Eli Lilly. What sets it apart from every metabolic peptide before it is the scope of its receptor activity: it is the first compound to simultaneously engage the GLP-1 receptor, the GIP receptor, and the glucagon receptor (GCGR) in clinical trials. This triple agonism is the defining characteristic of the molecule, and the source of considerable research interest.

To understand why that matters, it helps to know what each receptor does:

• GLP-1 receptor: Drives satiety signaling, slows gastric emptying, and promotes glucose-dependent insulin secretion. This is the same receptor targeted by semaglutide (Ozempic, Wegovy).
• GIP receptor: Amplifies the incretin response, influences fat metabolism in adipose tissue, and contributes to insulin potentiation. This is the second target of tirzepatide (Mounjaro, Zepbound).
• Glucagon receptor: Increases energy expenditure through thermogenesis and drives hepatic fatty acid oxidation — the mechanism most associated with liver fat clearance. This is the dimension that tirzepatide does not cover.

By adding the glucagon receptor to the mix, retatrutide introduces a thermogenic and hepatic component that GLP-1-only and GLP-1/GIP dual agonists lack. Researchers hypothesize this is why the compound’s effects on both body weight and liver fat appear to exceed what earlier generation agonists have achieved (Jastreboff et al., NEJM 2023).

Receptor Potency at a Glance

In vitro studies have characterized retatrutide’s binding affinity at each receptor using EC50 values. It shows highest potency at the GIP receptor (EC50: 0.0643 nM), intermediate potency at the GLP-1 receptor (EC50: 0.775 nM), and lower — but physiologically relevant — potency at the glucagon receptor (EC50: 5.79 nM). This graduated profile is thought to reflect a deliberate design choice: strong incretin agonism with more measured glucagon activation, balancing metabolic benefits against the glucose-raising effects that pure glucagon would produce.

Key Clinical Trial Results

The landmark Phase 2 trial, published in the New England Journal of Medicine in June 2023, enrolled 338 adults with obesity or overweight and ran for 48 weeks. The top-line findings were striking (NEJM, 2023):

• Mean body weight reduction of 24.2% at the highest dose (12 mg), versus 2.1% for placebo
• A clear dose-response relationship across the 1 mg, 4 mg, 8 mg, and 12 mg cohorts
• Approximately 26% of participants at the highest dose achieved ≥30% body weight reduction — a threshold rarely seen with any pharmacological intervention
• No apparent plateau at 48 weeks in the higher-dose groups, suggesting weight loss was still progressing at trial end

A parallel Phase 2 trial in people with type 2 diabetes, published in The Lancet, also demonstrated significant HbA1c reductions alongside the body weight effects (Lancet, 2023).

In December 2025, the first Phase 3 readout — from the TRIUMPH-4 trial — confirmed and extended the Phase 2 findings in a larger population. Participants receiving the highest dose achieved weight reductions of 26.4% to 28.7%, and the trial met its co-primary endpoint for reduction in knee osteoarthritis pain, making it the first evidence that a metabolic peptide of this class could produce measurable musculoskeletal benefit. Eli Lilly published the results via investor communication in December 2025, with full peer-reviewed publication expected in 2026 (Lilly Investor Relations).

Liver Fat Research

The most remarkable secondary finding in retatrutide research has come from MASLD (metabolic-associated steatotic liver disease) studies. A Phase 2a trial published in Nature Medicine reported 82–86% relative reduction in liver fat content as measured by MRI-PDFF at 48 weeks, with over 85% of subjects achieving resolution of hepatic steatosis (liver fat below 5%) (Nature Medicine, 2024). This greatly exceeds what has been observed with GLP-1-only or GLP-1/GIP agonists and is widely attributed to the glucagon receptor component’s direct stimulation of hepatic fatty acid oxidation.

Current Research Status

As of April 2026, retatrutide is in Phase 3 development under Eli Lilly’s TRIUMPH program. Active trials span obesity without diabetes (TRIUMPH-1), obesity with type 2 diabetes (TRIUMPH-2), weight maintenance (TRIUMPH-3), MASLD with histological endpoints, obstructive sleep apnea, and a cardiovascular outcomes trial. Regulatory submission is anticipated in late 2026 to mid-2027. The compound is not approved by the FDA or any regulatory body and is available only as a research peptide for laboratory investigation.

References:

• Jastreboff et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” NEJM, 2023.
• Rosenstock et al. “Retatrutide in type 2 diabetes.” The Lancet, 2023.
• Sanyal et al. “Retatrutide in MASLD.” Nature Medicine, 2024.
• “Retatrutide: Game Changer in Obesity Pharmacotherapy.” PMC.